Medacta Group SA (MOVE.SW) Stock
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Ownership
Peer Comparison
About Medacta Group SA
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Medacta Group SA is led by CEO Francesco Siccardi, employs 2,036 people, headquartered in Castel San Pietro, CH, publicly traded since 2019.
Medacta Group SA (MOVE.SW) stock trades at $132.80 with a market capitalization of $2.64B. The stock is valued at a price-to-earnings (P/E) ratio of 29.71, price-to-book of 6.21, price-to-sales of 3.87. Over the past 52 weeks the stock has ranged between $128.20 and $177.20, and currently trades 25.1% below its 52-week high. It pays a dividend yielding 0.84%.
On profitability, Medacta Group SA generates a return on equity (ROE) of 22.83% — well above the market average, a sign of a high-quality business, an operating margin of 15.96%, a net profit margin of 13.96%.
Official website: www.medacta.com